The U.S. Food and Drug Administration has approved Zepatier with or without ribavirin for the treatment of chronic Hepatitis C genotypes 1 and 4 infections in adult patients.
Tag Archive for: FDA
A network building capacity to prevent, manage and treat hepatitis B and C in NYC
Upcoming Events
There are no upcoming events.
News & Recent Posts
- Job | Hep C Care Coordinator @ OnPoint NYC October 29, 2025
- Funding | Treat, Cure & Eliminate Hep C (Deadline November 18) October 6, 2025
- Hep Free NYC Meeting Highlights | 09-10-2025 September 28, 2025
- Opportunity | Harm Reduction Peer Academy (Deadline September 26, 2025) September 4, 2025
- Funding | Concept Paper: Integrated Infectious Disease Testing and Linkage to Care for People Who Use Drugs (Due August 29, 2025) August 22, 2025
